S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33

Exelixis (EXEL) Stock Forecast, Price & News

+0.38 (+2.13%)
(As of 05/26/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
3.09 million shs
Average Volume
2.44 million shs
Market Capitalization
$5.83 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

Exelixis logo

About Exelixis

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.


Exelixis (NASDAQ:EXEL) Stock Rating Lowered by StockNews.com
Exelixis: Becoming A Giant Pharma - Seeking Alpha
Can This Cancer Stock Maintain Its Momentum?
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.43 billion
Cash Flow
$0.81 per share
Book Value
$7.15 per share


Net Income
$231.06 million
Pretax Margin




Free Float
Market Cap
$5.83 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.76 out of 5 stars

Medical Sector

43rd out of 1,424 stocks

Biological Products, Except Diagnostic Industry

4th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

Is Exelixis a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exelixis stock.
View analyst ratings for Exelixis
or view top-rated stocks.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 9,990,000 shares, an increase of 23.0% from the April 30th total of 8,120,000 shares. Based on an average trading volume of 2,520,000 shares, the days-to-cover ratio is currently 4.0 days.
View Exelixis' Short Interest

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Exelixis

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.07. The biotechnology company earned $356 million during the quarter, compared to analysts' expectations of $363.22 million. Exelixis had a trailing twelve-month return on equity of 13.77% and a net margin of 19.60%. The business's revenue was up 31.7% on a year-over-year basis.
View Exelixis' earnings history

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.63 billion, compared to the consensus revenue estimate of $1.64 billion.

What price target have analysts set for EXEL?

7 equities research analysts have issued twelve-month price objectives for Exelixis' shares. Their forecasts range from $28.00 to $42.00. On average, they expect Exelixis' share price to reach $32.29 in the next year. This suggests a possible upside of 77.5% from the stock's current price.
View analysts' price targets for Exelixis
or view top-rated stocks among Wall Street analysts.

Who are Exelixis' key executives?
Exelixis' management team includes the following people:
  • Dr. Stelios Papadopoulos Ph.D., Co-Founder & Independent Chair of the Board (Age 74, Pay $98k)
  • Dr. Michael M. Morrissey Ph.D., CEO, Pres & Director (Age 61, Pay $2.37M)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 54, Pay $1.09M)
  • Dr. Peter Lamb Ph.D., Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 61, Pay $909.46k)
  • Mr. Jeffrey J. Hessekiel J.D., Exec. VP, Gen. Counsel & Sec. (Age 53, Pay $957.2k) (LinkedIn Profile)
  • Mr. Patrick J. Haley M.B.A., MBA, Exec. VP of Commercial (Age 46, Pay $846.43k) (LinkedIn Profile)
  • Dr. Dana T. Aftab Ph.D., Exec. VP of Bus. Operations
  • Ms. Susan T. Hubbard, Exec. VP of Public Affairs & Investor Relations
  • Mr. Gregg Bernier, VP of Marketing
  • Ms. Laura Dillard, Exec. VP of HR
What is Michael M. Morrissey's approval rating as Exelixis' CEO?

32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among Exelixis' employees.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.27%), Vanguard Group Inc. (9.45%), Renaissance Technologies LLC (5.27%), JPMorgan Chase & Co. (3.76%), State Street Corp (3.55%) and Farallon Capital Management LLC (3.28%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends for Exelixis

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Polar Capital Holdings Plc, Candriam Luxembourg S.C.A., Meditor Group Ltd, EULAV Asset Management, Great Point Partners LLC, UBS Group AG, and Eversept Partners LP. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Peter Lamb, and Stelios Papadopoulos.
View insider buying and selling activity for Exelixis
or view top insider-selling stocks.

Which institutional investors are buying Exelixis stock?

EXEL stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, American Century Companies Inc., First Trust Advisors LP, BlackRock Inc., LSV Asset Management, Goldman Sachs Group Inc., Meritage Portfolio Management, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Exelixis
or or view top insider-buying stocks.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $18.19.

How much money does Exelixis make?

Exelixis has a market capitalization of $5.83 billion and generates $1.43 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.92 on an earnings per share basis.

How many employees does Exelixis have?

Exelixis employs 954 workers across the globe.

When was Exelixis founded?

Exelixis was founded in 1994.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at (650) 837-7000, via email at [email protected], or via fax at 650-837-8300.

This page was last updated on 5/27/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.